Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis?
Gentiletti
Julieta
J
Fava
Roy A
RA
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D004357:Drug Synergism; D016228:Endothelial Growth Factors / Q000378:metabolism*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D007375:Interleukin-1 / Q000494:pharmacology; D008222:Lymphokines / Q000378:metabolism*; D019947:Receptors, Interleukin-6 / Q000276:immunology*; D013583:Synovial Membrane / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000093242:Interleukin-6 Inhibitors
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D007375:Interleukin-1; D008222:Lymphokines; D019947:Receptors, Interleukin-6; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000093242:Interleukin-6 Inhibitors